Estimates of vaccine effectiveness against measles and mumps: 14 years follow-up of a large cohort in Wales, UK
International Journal of Epidemiology · 17.04.2026 · 55 (3)
DOI: 10.1093/ije/dyag083 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Epidemiology, online erschienen am 06.06.2026. Verfasst von Malorie Perry und 4 weiteren Autor:innen. Beteiligte Einrichtung: Population Data Science, Health Data Research UK, Swansea University Medical School, Swansea, SA2 8PP, Wales, United Kingdom. Hauptthemen laut MEDLINE: Mumps, Measles, Measles-Mumps-Rubella Vaccine, Vaccine Efficacy. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Uptake of the measles–mumps–rubella vaccine in Wales is high. However, sporadic measles cases still occur and there are large mumps outbreaks every few years. In this study, the long-term vaccine effectiveness (VE) of vaccines containing measles and mumps is assessed.
Methods
A retrospective cohort of 822 116 individuals aged 1–30 years were followed up between 1 January 2007 and 31 December 2020. Welsh Demographic Service data were linked to vaccination status from the national vaccination register and primary care records. Outcomes were identified by linking to laboratory confirmations (measles and mumps) and notifications (mumps) data. Complications were sourced from hospital admissions and primary care data. Extended Cox regression was used to calculate hazard ratios.
Results
The adjusted VE (aVE) against confirmed measles after two doses remained high after 15 years 99.7% [95% confidence interval (CI) 99.2–99.9]. The aVE for confirmed mumps was lower, with decline over time: 93.6% (95% CI 90.2–95.8) in the first 5 years after vaccination with dose two and 49.9% (95% CI 34.4–61.8) after ≥15 years. A third dose of mumps vaccine temporarily increases protection (87.6%, 95% CI 71.7–94.6). The aVE estimates for mumps were lower when based on clinical suspicion. The VE was high against complications for both infections.
Conclusion
The high, sustained VE for measles strengthens evidence that elimination remains possible and the high VE against mumps complications is encouraging. Evidence for the waning of mumps immunity may be important when deciding to implement a third dose in outbreak settings. With the increased use of data linkage, studies should be conducted to corroborate these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Population Data Science, Health Data Research UK, Swansea University Medical School, Swansea, SA2 8PP, Wales, United Kingdom.
- Vaccine Preventable Disease Programme and Communicable Disease Surveillance Centre, Public Health Wales, Cardiff, CF10 4BZ, Wales, United Kingdom.
- Wales Specialist Virology Centre, University Hospital of Wales, Cardiff, CF14 4XW, Wales, United Kingdom.
ORCID-Profile: Malorie Perry
Zitieren
APA
Perry, M., Gravenor, M. B., Cottrell, S., Moore, C., & Griffiths, L. J. (2026). Estimates of vaccine effectiveness against measles and mumps: 14 years follow-up of a large cohort in Wales, UK. International Journal of Epidemiology, 55(3). https://doi.org/10.1093/ije/dyag083
Vancouver
Perry M, Gravenor MB, Cottrell S, Moore C, Griffiths LJ. Estimates of vaccine effectiveness against measles and mumps: 14 years follow-up of a large cohort in Wales, UK. International Journal of Epidemiology. 2026;55(3). doi:10.1093/ije/dyag083
BibTeX
@article{Perry2026,
author = {Perry, Malorie and Gravenor, Michael B and Cottrell, Simon and Moore, Catherine and Griffiths, Lucy J},
title = {Estimates of vaccine effectiveness against measles and mumps: 14 years follow-up of a large cohort in Wales, UK},
journal = {International Journal of Epidemiology},
year = {2026},
volume = {55},
number = {3},
doi = {10.1093/ije/dyag083}
}
EUVIMED